Israel Purchases COVID-19 Vaccines for 2022

Massachusetts-based Moderna, Inc. announced a new supply agreement with the State of Israel for 2022. Under the terms of this agreement confirmed on April 20, 2021, Israel retains an option to purchase doses of one of Moderna’s variant-specific vaccine candidates subject to regulatory approval.

Today’s announcement follows two earlier agreements between Israel and Moderna to supply a total of 10 million doses of the COVID-19 Vaccine Moderna, which the Israeli Ministry of Health authorized on January 4, 2021.

Stéphane Bancel, CEO of Moderna, stated in a press release, “Recent preclinical results have shown that our variant-specific booster candidates were effective against COVID-19 variants of concerns, and we hope to continue to see positive results from the clinical studies.”

The experimental COVID-19 Vaccine Moderna is an mRNA vaccine against COVID-19 encoding for a prefusion stabilized form of the Spike protein, which was co-developed by Moderna and investigators from the US National Institute of Allergy and Infectious Diseases’ Vaccine Research Center.

Moderna's COVID-19 vaccine received an Emergency Authorization and has not been Approved by the U.S. FDA.

Cambridge-based Moderna has transformed into an enterprise with a diverse clinical portfolio of vaccines and therapeutics across six modalities, a broad intellectual property portfolio in areas including mRNA and lipid nanoparticle formulation, and an integrated manufacturing plant that allows for both clinical and commercial production at scale and unprecedented speed.